Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.63 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31457850 | 1.00 | PLA2G4B (0.63) | PLA2G4BPTPN11ITGB3ITGA2BCYP4F2 | |
| SCHEMBL31457781 | 1.00 | PLA2G4B (0.63) | PLA2G4BPTPN11ITGB3ITGA2BCYP4F2 | |
| SCHEMBL31457788 | 1.00 | PLA2G4B (0.63) | PLA2G4BPTPN11ITGB3ITGA2BCYP4F2 | |
| SCHEMBL31457813 | 0.98 | PLA2G4B (0.61) | PLA2G4BPTPN11ITGB3ITGA2BCYP4F2 | |
| SCHEMBL25081993 | 0.92 | PLA2G4B (0.71) | PLA2G4BPTPN11CYP4F2CYP4A11PPARD | |
| SCHEMBL30278806 | 0.92 | PLA2G4B (0.71) | PLA2G4BPTPN11CYP4F2CYP4A11PPARD | |
| SCHEMBL25081988 | 0.92 | PLA2G4B (0.71) | PLA2G4BPTPN11CYP4F2CYP4A11PPARD | |
| SCHEMBL30278812 | 0.92 | PLA2G4B (0.71) | PLA2G4BPTPN11CYP4F2CYP4A11PPARD | |
| SCHEMBL25081987 | 0.92 | PLA2G4B (0.71) | PLA2G4BPTPN11CYP4F2CYP4A11PPARD | |
| SCHEMBL25081990 | 0.91 | PLA2G4B (0.68) | PLA2G4BPTPN11CYP4F2CYP4A11PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. | 2025-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | PLA2G4B 2881/4885PTPN11 4337/4885ITGB3 4085/4885 |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | PLA2G4B 1667/4885PTPN11 4105/4885ITGB3 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.